StockNews.com Initiates Coverage on vTv Therapeutics (NASDAQ:VTVT)

Investment analysts at StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners assumed coverage on vTv Therapeutics in a report on Monday, December 9th. They issued a “buy” rating and a $35.00 price target for the company.

vTv Therapeutics Stock Performance

Shares of VTVT opened at $17.14 on Monday. The company has a market cap of $54.68 million, a price-to-earnings ratio of -3.78 and a beta of 1.07. The stock has a fifty day moving average price of $16.16 and a two-hundred day moving average price of $15.34. vTv Therapeutics has a 52-week low of $12.12 and a 52-week high of $30.99.

Institutional Trading of vTv Therapeutics

Hedge funds have recently modified their holdings of the stock. FMR LLC acquired a new position in vTv Therapeutics during the 3rd quarter worth $2,402,000. Geode Capital Management LLC increased its stake in shares of vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 1,327 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics during the fourth quarter worth $25,000. 17.51% of the stock is owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.